European Pharmaceutical Review
FEBRUARY 27, 2024
The facility has been designed to meet the highest environmental sustainability standards, to help Amgen’s reach its target of carbon neutrality in all operations by 2027, the company noted. .” Amgen Ohio is nearly 300,000 ft 2 in size and will employ 400 full-time staff.
FDA Law Blog: Biosimilars
AUGUST 23, 2023
FDA has made good progress on these initial goals, providing updates on the first four on the Digital Health Technologies (DHTs) for Drug Development website. Earlier this year, FDA published the Framework for the Use of Digital Health Technologies in Drug and Biological Product Development (DHT Framework).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Syner-G
JULY 7, 2023
Cell and gene therapies have been subjects of research for some time, but they have gained traction in real-world medicine and are projected to reach a market value of more than $36 billion by 2027. Drug development companies must embrace new technology. Efficient clinical and commercial manufacturing presents issues, too.
pharmaphorum
JANUARY 27, 2022
The inaugural LNP Formulation & Process Development Summit is the industry’s first forum dedicated to bringing together drug developers within the LNP field to share the latest scientific breakthroughs on formulation and process development. billion by 2027.
European Pharmaceutical Review
JANUARY 10, 2023
The report offers predictive analysis of drugs entering the market or launching key indications in 2023. Treatments identified in the report are predicted to be potential blockbuster drugs by 2027 or have potential to serve unmet patient needs for millions of patients worldwide. Drug development in 2023 and beyond.
European Pharmaceutical Review
APRIL 14, 2023
Oligonucleotide therapeutics represent a relatively novel class of drug, with the potential to modulate drug targets that were previously considered intractable, and with the benefit of fast clinical development times. Success rates in all stages of development is really low. Oligonucleotide synthesis market to reach $16.7
pharmaphorum
JANUARY 18, 2022
million in 2020 and with the rapid growth of the industry, is expected to grow at a CAGR of 8.95% up to 2027. Smart device developers. Training device developers. Drug developers. Device innovations, connected delivery and regulatory guidance for advanced parenteral systems. Medical Device Engineers.
Expert insights. Personalized for you.
99 
Let's personalize your content